Kyprolis is a cancer medicine used together with the medicines daratumumab and dexamethasone, or lenalidomide and dexamethasone or with dexamethasone alone, to treat multiple myeloma (a cancer of the bone marrow). It is given to adults who have received at least one previous treatment for their cancer. Kyprolis contains the active substance carfilzomib. Multiple myeloma is rare, and Kyprolis was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 3 June 2008.
Therapeutic Indication
### Therapeutic indication Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Therapeutic Area (MeSH)
N/AATC Code
L01XX45
ATC Item
xl 01 xx 45
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| carfilzomib | N/A | 卡非佐米 |
EMA Name
Kyprolis
Medicine Name
Kyprolis
Aliases
N/ANo risk management plan link.
